Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting.

To characterize clinical outcomes following a single administration of bimatoprost SR in eyes with glaucoma in a real-world setting implanted at the slit-lamp. Tertiary care Glaucoma practice, Glaucoma Associates of Texas, Dallas, Texas. Retrospective interventional case series. Data were analyzed from consecutive patients receiving a single bimatoprost SR implant from the time of its approval to the time of data collection. All eyes were implanted at the slit-lamp. Eyes with less than 1 month of follow-up were excluded. The primary outcome was median time to next intraocular pressure (IOP)-lowering intervention. Mean IOP and medication use, and changes from baseline, were also assessed through 12 months of follow-up. Overall 129 eyes of 81 patients were analyzed. Following bimatoprost SR administration (replacing a topical prostaglandin analogue [PGA] in most eyes), the median survival time without any further IOP-lowering interventions was between 6-9 months. Mean IOP remained unchanged from baseline at month 1 (consistent with switch from topical to intracameral PGA therapy) and began to rise at month 3. At month 12, 40.5% of eyes (52 eyes) remained intervention-free, mean medication reduction was 0.5 medications per eye, and 27.8% of eyes (36 eyes) were medication-free. Adverse events were uncommon and most were transient and resolved with or without intervention. This real-world analysis of bimatoprost SR use for glaucoma therapy complements Phase 3 study findings and demonstrates that the implant can safely provide medication reduction through 6 months in most eyes and through 12 months in almost 40% of eyes.

Informations de copyright

© 2024 Ali et al.

Déclaration de conflit d'intérêts

DSG is a consultant for Allergan and reports grants/personal fees for Medical Advisory Board from Belkin Vision, CATS tonometer, Reichert, Sanoculis, Versant Health and iStar Medical; grants/personal fees from New World Medical and Regeneron; personal fees and minority equity ownership from Nova Eye Medical and Olleyes, outside the submitted work. The authors report no other conflicts of interest in this work.